Prenetics Global Limited (NASDAQ:PRE) Short Interest Update

Prenetics Global Limited (NASDAQ:PRE) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totalling 41,900 shares, an increase of 23.6% from the November 30th total of 33,900 shares. Approximately 0.5% of the company’s shares are sold short. Based on an average trading volume of 14,000 shares, the short-interest ratio is presently 3.0 days.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $9.00 price objective on shares of Prenetics Global in a report on Wednesday, December 4th.

Prenetics Global Price Performance

PRE traded down $0.03 on Tuesday, hitting $5.80. The company had a trading volume of 10,471 shares, compared to its average volume of 47,859. Prenetics Global has a 52-week low of $2.85 and a 52-week high of $7.84. The stock has a fifty day simple moving average of $4.90 and a 200-day simple moving average of $5.11. The firm has a market capitalization of $52.99 million, a P/E ratio of -1.45 and a beta of -0.18.

Prenetics Global (NASDAQ:PRE) last released its earnings results on Monday, October 7th. The company reported ($0.88) EPS for the quarter. The firm had revenue of $5.94 million during the quarter. Prenetics Global had a negative net margin of 191.73% and a negative return on equity of 16.45%. Equities research analysts expect that Prenetics Global will post -3.3 earnings per share for the current fiscal year.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.